Inhibikase Therapeutics Inc. (IKT) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Inhibikase Therapeutics Inc., updated every trading day.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Price
$1.62
+3.18% today
Market cap
$219M
Overall quality
—
Kronos AI 30-day
+26.0%
8 of 8 simulated paths end higher
Inhibikase Therapeutics Inc. (IKT) is a Health Care company in Biotechnology: Biological Products (No Diagnostic Substances), worth $219M. It trades at $1.62, up 3.18% today. 5 analysts' average target of $5.50 implies +239.5% from today's price. Kronos AI's 30-day forecast is +26.0% (8 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $5.50 |
| Low – high | $1.50 – $8.00 |
| Analysts | 5 |
| Upside to average | +239.5% |
Kronos AI 30-day forecast
| Expected close | $1.98 (+26.0%) |
| Likely range | +21.0% … +29.8% |
| As of | 2026-10-27 |
8 of 8 simulated paths end higher.
Quality scores
Not scored: the financial data for this listing is incomplete.
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Biotechnology: Biological Products (No Diagnostic Substances)
For information only, not investment advice. Prices updated: 2026-10-29.